FDA permits use of icometrix's AI-based quantification for chest CT in COVID-19

LEUVEN, Belgium and CHICAGO, May 12, 2020 /PRNewswire/ -- icometrix announced today that the FDA has allowed the clinical use of their icolung AI algorithms for fast and objective quantification of lung pathology on chest CT scans in admitted COVID-19 patients.

The AI algorithm, icolung, quantifies the degree of lung involvement in COVID-19 patients on CT in different lung regions and per type of CT findings (Ground Glass Opacity, Consolidation, and Crazy Paving Pattern). Quantification can help radiologists to assess the pulmonary status, as recommended by the Fleischner Society Consensus Statement. Automated quantification introduces consistency and objectivity in the assessment of regional lung pathology and can assist with the risk-based triage of COVID-19 patients with moderate to severe symptoms.

"AI should complement radiologists, extending beyond detection of lung abnormalities to identifying COVID-suggestive patterns and quantifying lung involvement to support risk assessment," says Dr. Lawrence Tanenbaum, VP and CTO at RadNet.

"We have been using icolung in clinical practice since its CE-marking and have seen that quantitative CT data is important in the triage of patients. The icolung AI tool can provide a clear percentage of affected tissue, which radiologists can't," says Prof. Johan de Mey, Head of Radiology at UZ Brussel. "Of course, we still look at the scans and the radiology expertise is very important, but it's great that this can go hand in hand with an accurate quantitative evaluation by AI."

The COVID-19 pandemic puts continuous pressure on the health care system. The potential waves of infection, together with the efforts to resume non-essential imaging and procedures, will prolong the high-pressure situation health care is currently facing. The need for triage and resource-allocation will remain vital throughout the next year.

About icolung

icolung is a cloud-based AI software, developed by researchers of ETRO, an imec research group of VUB, and ESAT-PSI of KU Leuven, to quantify disease burden in COVID-19 patients on non-contrast chest CT. icolung quantifies total and regional lesion burden and returns a concise report and annotated images directly into the hospital PACS, within 10 min. icolung is the result of an ongoing collaboration, further improvements, and developments of the icolung algorithm are automatically deployed to all users via the cloud. icolung received CE-marking for clinical use in Europe on April 23, 2020, and is currently offered pro bono worldwide.

About icometrix

icometrix is the world leader in software solutions to obtain clinically meaningful data from brain MR and CT scans for patients with neurological conditions such as multiple sclerosis, brain trauma, epilepsy, dementia, Alzheimer's, Parkinson's, etc. The fully automated icobrain software from icometrix is FDA cleared and CE labeled and leverages artificial intelligence to quantify disease-specific brain structures in individual patients. Today, icometrix is internationally active in over 100 clinical practices and works with healthcare providers and pharmaceutical companies on the evaluation of drug trials for neurological diseases.

More info

icometrix.com
Press Kit: https://tinyurl.com/y8y3jtqa

Dirk Smeets, CTO
[email protected]
+32 495 80 16 46

SOURCE icometrix

Related Links

https://icometrix.com/